GIT 27

Cat. No. 3270

GIT 27 C11H11NO3 [6501-72-0]

Price and Availability

For GIT 27 pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 4,5-Dihydro-3-phenyl-5-isoxazoleacetic acid

Biological Activity

Orally active immunomodulatory agent that primarily targets macrophages. Inhibits TNF-α secretion via interference of macrophage toll-like receptor (TLR) 4 and TLR 2/6 signaling pathway. Also reduces the secretion of pro-inflammatory cytokines IL1-β, IL-10 and IFN-γ. Antidiabetogenic; prevents IL-β and IFN-γ-induced pancreatic islet cell death in vitro.

Technical Data

Soluble to 100 mM in DMSO
>99 %
Store at +4°C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet


Stojanovic et al (2007) In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin.Immunol. 123 311. PMID: 17449326.

Stosic-Grujicic et al (2007) A potent immunomodulatory compound (S,R)-3-phenyl-4,5-dihydro-5-isoxasoleacetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J.Pharmacol.Exp.Ther. 320 1038. PMID: 17148780.

Mangano et al (2008) In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. Eur.J.Pharmacol. 586 313. PMID: 18374912.

If you know of a relevant citation for this product please let us know.

Keywords: GIT 27, supplier, Interfers, TLR4, TLR2/6, signalling, Immunomodulators, reduces, production, pro-inflammatory, cytokines, Toll-like, Receptors, TNF-α, TNF-alpha, Interleukins, Tumor, Necrosis, Factor-α, Factor-alpha, Cytokines, Cytokine, NF-κB, NF-kappaB, Signaling, Signalling, GIT27

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide


Highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Immunology Guide


Highlights over 190 products for immunology research. Request copy or view PDF today.

divider line

New Therapies and Challenges in Asthma

Written by Peter J. Barnes

Asthma Life Science Poster

'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development. Request copy today.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Life Science Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance. Request copy today.

divider line

Peripheral Sensitization

Written by Grant D. Nicol and Michael R. Vasko

Pain Life Science Poster

A summary of the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. Request copy or view PDF today.

divider line

New Products in this Area


Stat3 inhibitor; blocks cancer stem cell self-renewal


mSTING agonist; induces antitumor immunological responses

C 87

TNF-α inhibitor

JTE 607 dihydrochloride

Cytokine release inhibitor; anti-inflammatory

Sign-up for new product e-alerts
divider line

Bio-Techne Events

Bio-Techne Symposium 2016

Stem Cells and Organoids as Models of Tissue Differentiation and Disease

January 12, 2016

London, UK